Shanghai Kaibao Pharmaceutical (SHE:300039) — Stock Price

CN¥5.84 CNY
▼ -2.01% today

Shanghai Kaibao Pharmaceutical (SHE:300039) is currently trading at CN¥5.84 CNY, down 2.01% today. Over the past 52 weeks, shares have ranged between CN¥4.18 and CN¥6.96. This page tracks Shanghai Kaibao Pharmaceutical's live share price on the SHE exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see how much is Shanghai Kaibao Pharmaceutical worth.

Shanghai Kaibao Pharmaceutical (300039) Stock Price Chart — Daily History & Trading Volume

The chart below tracks Shanghai Kaibao Pharmaceutical's daily closing share price and trading volume on the SHE exchange over the past year, giving a clear view of recent price momentum and liquidity.

Shanghai Kaibao Pharmaceutical Income Statement — Revenue, Profit & Earnings by Year

Shanghai Kaibao Pharmaceutical's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.

Fiscal Year 20242023202220212020
Total Revenue CN¥1.47 Billion CN¥1.59 Billion CN¥1.12 Billion CN¥1.10 Billion CN¥908.01 Million
Cost of Revenue CN¥272.76 Million CN¥311.82 Million CN¥247.57 Million CN¥234.92 Million CN¥179.85 Million
Gross Profit CN¥1.20 Billion CN¥1.28 Billion CN¥871.28 Million CN¥865.66 Million CN¥728.16 Million
Research & Development CN¥99.79 Million CN¥95.87 Million CN¥52.97 Million CN¥79.32 Million CN¥59.12 Million
SG&A CN¥35.13 Million CN¥43.37 Million CN¥17.62 Million CN¥20.92 Million CN¥30.91 Million
Total Operating Expenses CN¥762.31 Million CN¥899.28 Million CN¥666.85 Million CN¥732.46 Million CN¥633.37 Million
Operating Income CN¥438.25 Million CN¥382.96 Million CN¥228.37 Million CN¥171.83 Million CN¥134.42 Million
EBITDA CN¥470.27 Million CN¥367.54 Million CN¥257.90 Million CN¥203.66 Million CN¥172.93 Million
EBIT CN¥434.22 Million CN¥330.01 Million CN¥226.18 Million CN¥169.80 Million CN¥131.91 Million
Interest Expense CN¥149.36K CN¥118.55K CN¥127.32K CN¥148.50K CN¥515.97K
Income Before Tax CN¥434.18 Million CN¥383.53 Million CN¥226.19 Million CN¥169.65 Million CN¥131.60 Million
Income Tax Expense CN¥59.27 Million CN¥56.63 Million CN¥36.11 Million CN¥29.54 Million CN¥25.48 Million
Net Income CN¥375.58 Million CN¥327.87 Million CN¥190.80 Million CN¥140.11 Million CN¥106.12 Million

Shanghai Kaibao Pharmaceutical Balance Sheet — Assets, Liabilities & Shareholder Equity

The balance sheet below summarizes Shanghai Kaibao Pharmaceutical's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.

Fiscal Year 20242023202220212020
Total Assets CN¥4.52 Billion CN¥4.58 Billion CN¥4.26 Billion CN¥3.36 Billion CN¥2.88 Billion
Total Current Assets CN¥2.42 Billion CN¥1.47 Billion CN¥1.57 Billion CN¥2.25 Billion CN¥2.22 Billion
Cash & Equivalents — — — — —
Short-term Investments CN¥180.02 Million CN¥150.01 Million CN¥136.07 Million CN¥51.26 Million CN¥114.65 Million
Net Receivables CN¥472.12 Million CN¥533.55 Million CN¥566.09 Million CN¥614.76 Million CN¥561.67 Million
Inventory CN¥187.85 Million CN¥171.79 Million CN¥160.80 Million CN¥165.14 Million CN¥191.54 Million
Property, Plant & Equipment — — — CN¥307.78 Million CN¥295.87 Million
Goodwill — — CN¥9.04 Million CN¥13.79 Million CN¥18.50 Million
Total Liabilities CN¥415.45 Million CN¥546.82 Million CN¥498.24 Million CN¥310.90 Million CN¥298.96 Million
Total Current Liabilities CN¥232.30 Million CN¥334.85 Million CN¥295.96 Million CN¥190.68 Million CN¥237.55 Million
Long-term Debt — — — — —
Net Debt CN¥-587.89 Million CN¥-601.94 Million CN¥-685.59 Million CN¥-1.34 Billion CN¥-1.27 Billion
Total Stockholder Equity CN¥4.10 Billion CN¥4.03 Billion CN¥3.76 Billion CN¥3.04 Billion CN¥2.58 Billion
Retained Earnings CN¥2.03 Billion CN¥1.80 Billion CN¥1.57 Billion CN¥1.38 Billion CN¥1.29 Billion

Shanghai Kaibao Pharmaceutical Cash Flow Statement — Operating, Investing & Financing Activities

This cash flow statement breaks down how Shanghai Kaibao Pharmaceutical generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.

Fiscal Year 20242023202220212020
Operating Cash Flow CN¥278.95 Million CN¥382.66 Million CN¥376.42 Million CN¥126.08 Million CN¥250.65 Million
Capital Expenditures CN¥140.52 Million CN¥29.08 Million CN¥31.62 Million CN¥42.55 Million CN¥13.94 Million
Free Cash Flow CN¥138.43 Million CN¥353.59 Million CN¥344.80 Million CN¥83.53 Million CN¥236.71 Million
Investing Cash Flow CN¥-33.43 Million CN¥-198.63 Million CN¥-285.37 Million CN¥-83.51 Million CN¥65.21 Million
Financing Cash Flow CN¥-99.23 Million CN¥-62.76 Million CN¥-52.30 Million CN¥-69.37 Million CN¥-69.39 Million
Dividends Paid CN¥104.64 Million CN¥62.76 Million CN¥52.30 Million CN¥31.38 Million CN¥104.60 Million
Stock-Based Compensation — — — — —
Depreciation CN¥36.05 Million CN¥37.53 Million CN¥31.71 Million CN¥33.86 Million CN¥40.81 Million
Change in Cash CN¥146.30 Million CN¥121.27 Million CN¥38.75 Million CN¥-26.80 Million CN¥246.47 Million

Shanghai Kaibao Pharmaceutical Earnings History — EPS Actual vs. Analyst Estimates

Track Shanghai Kaibao Pharmaceutical's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.

Report Date EPS Actual EPS Estimate Surprise
Sep 30, 2025 0.06 — —
Jun 30, 2025 0.04 — —
Jun 05, 2025 0.08 — —
Oct 25, 2024 0.07 — —
Aug 29, 2024 0.05 — —
Jun 05, 2024 0.13 — —
Oct 20, 2023 0.06 — —
Aug 09, 2023 0.05 — —